Piramal Pharma receives EIR from USFDA for Telangana facility

Piramal Pharma Ltd. on Monday, May 18, said the US Food and Drug Administration (USFDA) has successfully closed the inspection of its manufacturing facility in Digwal, Telangana.In an exchange filing, the company said the USFDA has issued an Establishment Inspection Report (EIR) for the facility, indicating the closure of the inspection process.

The company had earlier informed the exchanges on February 14, 2026, about the USFDA inspection at the Digwal manufacturing unit.
The Digwal facility is one of the company’s manufacturing sites in India, catering to global markets.Last month, the USFDA issued an EIR for the company’s manufacturing facility in Lexington, Kentucky, which concluded with a Voluntary Action Indicated (VAI) status, indicating that while certain observations may have been noted, no immediate regulatory action is required.

Last month, Chairperson of the company, Nandini Piramal, said Piramal Pharma expects growth to pick up in FY27 after a transitional FY26. The momentum will be supported by improving demand in its contract development and manufacturing (CDMO) business and new product additions, she said.

Shares of the company were trading almost 1% down at ₹173.25 as of 12.05 pm on Monday. The stock has fallen close to 16% over the last year.

Also Read: Jana Small Finance Bank approves ₹728 crore fund raise via preferential issue; Check list of investors